Skip to content
MarketScale
‹ Back to IndustriesHealthcare

THE PERFECT BLEND OF SCIENCE TO SATISFY YOUR GUT

It’s fairly common knowledge that antibiotics are used frequently to treat a variety of bacterial infections—some of the most common are urinary tract infections, strep throat, and even some pneumonia. Antibiotics kill or prevent bacteria from reproducing, allowing the body’s natural defenses to eliminate the illness-causing pathogen. Not all bacteria and other microorganisms are harmful “germs”….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

It’s fairly common knowledge that antibiotics are used frequently to treat a variety of bacterial infections—some of the most common are urinary tract infections, strep throat, and even some pneumonia. Antibiotics kill or prevent bacteria from reproducing, allowing the body’s natural defenses to eliminate the illness-causing pathogen. Not all bacteria and other microorganisms are harmful “germs”. In fact, many microorganisms help our bodies function properly, such as the bacteria that are normally present in our intestines that help digest food, destroy disease-causing microorganisms, and produce vitamins.

While antibiotics are very effective in targeting the pathogenic bacteria that they are prescribed to eliminate, they also wipe out a large amount of the normal, beneficial bacteria that we have in our gut. It’s not unexpected for an infection to cause digestive-related problems, but it’s important to know that the antibiotic itself may also cause issues– most commonly, diarrhea.

Probiotics, on the other hand, are live bacteria that provide health benefits. A wide range of products are sold as probiotics, including foods (like yogurt), drinks and dietary supplements. Many of the probiotic strains are the same as or similar to those that naturally live in our bodies. So, should you take probiotics when you are prescribed antibiotics? Let’s take a closer look.

In a study published in the Journal of American Medical Association, researchers reviewed 63 randomized controlled trials of nearly 12,000 patients and their use of probiotics for the prevention or treatment of antibiotic-associated diarrhea (AAD). Patients were being treated for a range of conditions, from ear infections to sepsis. The study concluded that 42% of patients were less likely to get diarrhea from their antibiotic drugs if they were also taking a probiotic.

Preliminary evidence indicates some probiotics may be helpful in the prevention and treatment of antibiotic-associated diarrhea (AAD), but more needs to be learned. Further study is required in order to determine which probiotics are the most effective and in what dosages. Researchers also need to determine which types of patients would most likely benefit from taking probiotics. Just remember, probiotics are not considered drugs, and are not approved for the treatment of any illness or disease.

Simply put, antibiotics often disrupt the gut’s microflora. The evidence seems to suggest that probiotics can help.

At Deerland Enzymes, we take pride in the science-supported dietary supplement formulations we develop with our customers. Our DE111® strain of Bacillus subtilis is a clinically studied probiotic spore which supports a proper balance of bacteria in the gut. To learn more, visit http://www.deerlandenzymes.com/de111/ today.

Read more at deerlandenzymes.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512